Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SEPN
stocks logo

SEPN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax
Wall Street analysts forecast SEPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEPN is 27.67 USD with a low forecast of 25.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast SEPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEPN is 27.67 USD with a low forecast of 25.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.160
sliders
Low
25.00
Averages
27.67
High
30.00
Current: 26.160
sliders
Low
25.00
Averages
27.67
High
30.00
JPMorgan
NULL -> Overweight
upgrade
$28 -> $34
2025-11-18
Reason
JPMorgan
Price Target
$28 -> $34
2025-11-18
upgrade
NULL -> Overweight
Reason
JPMorgan raised the firm's price target on Septerna to $34 from $28 and keeps an Overweight rating on the shares following a transfer of coverage. The firm remains "optimistic" about the stock's potential upside as the company's Native Complex Platform platform is validated.
Wells Fargo
Derek Archila
Equal Weight -> Overweight
upgrade
$18 -> $28
2025-11-14
Reason
Wells Fargo
Derek Archila
Price Target
$18 -> $28
2025-11-14
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo analyst Derek Archila upgraded Septerna to Overweight from Equal Weight with a price target of $28, up from $18.
Wells Fargo
Equal Weight -> Overweight
upgrade
$18 -> $28
2025-11-14
Reason
Wells Fargo
Price Target
$18 -> $28
2025-11-14
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Septerna to Overweight from Equal Weight with a price target of $28, up from $18, after hosting investor meetings with management. The firm "gained confidence" on SEP-479's safety profile and its "differentiation" relative to Septerna's prior program. Wells sees SEP-479's advancement into Phase 1 and SEP-631's Phase 1 update in the first half of 2026 as key catalysts for the stock.
H.C. Wainwright
Buy
maintain
$26 -> $30
2025-11-11
Reason
H.C. Wainwright
Price Target
$26 -> $30
2025-11-11
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Septerna to $30 from $26 and keeps a Buy rating on the shares. The firm says the SEP-631 clinical data release is on track for a first half of 2026 readout.
H.C. Wainwright
H.C. Wainwright
initiated
$26
2025-06-23
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$26
2025-06-23
initiated
Reason
Wells Fargo
Derek Archila
Hold
Maintains
$14 → $11
2025-03-28
Reason
Wells Fargo
Derek Archila
Price Target
$14 → $11
2025-03-28
Maintains
Hold
Reason
Wells Fargo lowered the firm's price target on Septerna to $11 from $14 and keeps an Equal Weight rating on the shares. Following the discontinuation of their former oral PTH1R agonist, SEP-786, management aims to identify a new oral PTH1R agent by year-end 2025. With that lack of clinical catalysts in the next 12-18 months, the firm remains on the sidelines. That said, Wells believes progress and candidate selection for Septerna's next-gen PTH program is an important near-term milestone.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Septerna Inc (SEPN.O) is -53.41, compared to its 5-year average forward P/E of -14.77. For a more detailed relative valuation and DCF analysis to assess Septerna Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-14.77
Current PE
-53.41
Overvalued PE
6.16
Undervalued PE
-35.69

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.37
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.27
Undervalued EV/EBITDA
-5.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
146.21
Current PS
0.00
Overvalued PS
455.10
Undervalued PS
-162.68
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

SEPN News & Events

Events Timeline

(ET)
2025-11-10
07:02:30
Septerna Announces Q3 Earnings Per Share of 18 Cents, Below Consensus Estimate of 79 Cents
select
2025-08-21 (ET)
2025-08-21
08:04:35
Septerna Administers Initial Doses to Participants in Phase 1 Trial of SEP-631
select
2025-05-15 (ET)
2025-05-15
16:09:33
Septerna reports Q1 EPS (49c), consensus (45c)
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-15NASDAQ.COM
Wells Fargo Raises Rating on Septerna (SEPN)

  • Wells Fargo Upgrade: On November 14, 2025, Wells Fargo upgraded Septerna's outlook from Equal-Weight to Overweight, with an average one-year price target of $23.46/share, indicating a potential 0.69% upside from its recent closing price.

  • Fund Sentiment: There are currently 186 funds reporting positions in Septerna, reflecting a slight decrease in ownership, while the average portfolio weight dedicated to SEPN has increased by 3.53%.

  • Institutional Holdings: Key shareholders include Ra Capital Management and Trv Gp V, with no changes in their holdings, while Driehaus Capital Management increased its stake by 4.87% and BVF decreased its holdings by 9.47%.

  • Market Outlook: The put/call ratio for SEPN stands at 2.57, suggesting a bearish sentiment in the market regarding the stock's future performance.

[object Object]
Preview
4.0
11-14Benzinga
Wells Fargo Boosts Septerna Rating to Overweight and Increases Price Target to $28

  • Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

  • Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

  • Market Intelligence: Benzinga Pro is positioned as a source for the most accurate and timely stock market intelligence available.

[object Object]
Preview
4.0
11-11Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Septerna, Increases Price Target to $30

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time market intelligence to help them succeed.

  • Exclusive Content: The platform features exclusive stories generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing insights and strategies.

  • Market Winning Tools: The service is designed to equip traders with the tools they need to make informed decisions and capitalize on market opportunities.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Septerna Inc (SEPN) stock price today?

The current price of SEPN is 26.16 USD — it has decreased -1.47 % in the last trading day.

arrow icon

What is Septerna Inc (SEPN)'s business?

Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.

arrow icon

What is the price predicton of SEPN Stock?

Wall Street analysts forecast SEPN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SEPN is 27.67 USD with a low forecast of 25.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Septerna Inc (SEPN)'s revenue for the last quarter?

Septerna Inc revenue for the last quarter amounts to 21.50M USD, increased 12113.07 % YoY.

arrow icon

What is Septerna Inc (SEPN)'s earnings per share (EPS) for the last quarter?

Septerna Inc. EPS for the last quarter amounts to 0.18 USD, decreased -102.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for Septerna Inc (SEPN)'s fundamentals?

The market is revising Downward the revenue expectations for Septerna, Inc. (SEPN) for FY2025, with the revenue forecasts being adjusted by -57.49% over the past three months. During the same period, the stock price has changed by 81.29%.
arrow icon

How many employees does Septerna Inc (SEPN). have?

Septerna Inc (SEPN) has 75 emplpoyees as of December 05 2025.

arrow icon

What is Septerna Inc (SEPN) market cap?

Today SEPN has the market capitalization of 1.17B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free